CR20110366A - Compuesto heterociclico y uso del mismo - Google Patents

Compuesto heterociclico y uso del mismo

Info

Publication number
CR20110366A
CR20110366A CR20110366A CR20110366A CR20110366A CR 20110366 A CR20110366 A CR 20110366A CR 20110366 A CR20110366 A CR 20110366A CR 20110366 A CR20110366 A CR 20110366A CR 20110366 A CR20110366 A CR 20110366A
Authority
CR
Costa Rica
Prior art keywords
heterociclical
compound
same
raf
inhibitory activity
Prior art date
Application number
CR20110366A
Other languages
English (en)
Inventor
Masanori Okaniwa
Terufumi Takagi
Hirose Masaaki
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42026212&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR20110366(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of CR20110366A publication Critical patent/CR20110366A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D277/82—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Se proporciona un derivado heterocíclico condensado que muestra una fuerte actividad inhibitoria de Raf.
CR20110366A 2008-12-02 2011-06-24 Compuesto heterociclico y uso del mismo CR20110366A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2008307581 2008-12-02
JP2009125256 2009-05-25

Publications (1)

Publication Number Publication Date
CR20110366A true CR20110366A (es) 2011-08-29

Family

ID=42026212

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20110366A CR20110366A (es) 2008-12-02 2011-06-24 Compuesto heterociclico y uso del mismo

Country Status (40)

Country Link
US (2) US8143258B2 (es)
EP (1) EP2358689B9 (es)
JP (1) JP5640014B2 (es)
KR (1) KR101639092B1 (es)
CN (1) CN102300854B (es)
AR (1) AR074435A1 (es)
AU (1) AU2009323274B2 (es)
BR (1) BRPI0922109A2 (es)
CA (1) CA2745144C (es)
CL (1) CL2011001299A1 (es)
CO (1) CO6400140A2 (es)
CR (1) CR20110366A (es)
CY (1) CY1117178T1 (es)
DK (1) DK2358689T5 (es)
DO (1) DOP2011000165A (es)
EA (1) EA019447B1 (es)
EC (1) ECSP11011165A (es)
ES (1) ES2557304T3 (es)
GE (1) GEP20146003B (es)
HR (1) HRP20151370T1 (es)
HU (1) HUE026491T4 (es)
IL (1) IL213184A0 (es)
JO (1) JO3101B1 (es)
MA (1) MA32911B1 (es)
ME (1) ME02331B (es)
MX (1) MX2011005836A (es)
MY (1) MY150989A (es)
NZ (1) NZ593759A (es)
PE (1) PE20110588A1 (es)
PL (1) PL2358689T3 (es)
PT (1) PT2358689E (es)
RS (1) RS54370B9 (es)
SG (1) SG171426A1 (es)
SI (1) SI2358689T1 (es)
SM (1) SMT201500316B (es)
TN (1) TN2011000280A1 (es)
TW (1) TWI436987B (es)
UY (1) UY32281A (es)
WO (1) WO2010064722A1 (es)
ZA (1) ZA201104659B (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2689514C (en) * 2007-06-05 2015-09-29 Takeda Pharmaceutical Company Limited Heterobicyclic compounds as kinase inhibitors
JP5270553B2 (ja) * 2007-08-23 2013-08-21 武田薬品工業株式会社 複素環化合物およびその用途
US8445509B2 (en) 2008-05-08 2013-05-21 Takeda Pharmaceutical Company Limited Fused heterocyclic derivatives and use thereof
EP2399921B1 (en) 2008-12-01 2015-08-12 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof
WO2013138753A1 (en) * 2012-03-16 2013-09-19 Fox Chase Chemical Diversity Center, Inc. Prodrugs of riluzole and their method of use
CN104428001A (zh) * 2012-03-30 2015-03-18 武田药品工业有限公司 Raf抑制剂和mek抑制剂在黑素瘤治疗中的投与
CN113679717A (zh) 2012-08-22 2021-11-23 康奈尔大学 用于抑制肌成束蛋白的方法
WO2014206344A1 (en) 2013-06-28 2014-12-31 Beigene, Ltd. Fused tricyclic amide compounds as multiple kinase inhibitors
KR102272606B1 (ko) 2013-06-28 2021-07-05 베이진 엘티디 Raf 키나아제 및/또는 raf 키나아제 이량체 저해제로서 융합 트리시클릭 우레아 화합물
CN103408541B (zh) * 2013-07-16 2015-04-01 浙江医药高等专科学校 吲哚取代的噻唑并环己烷类化合物、及其抗肿瘤用途
CN103382190B (zh) * 2013-07-16 2015-01-14 浙江医药高等专科学校 一类噻唑并环己烷类化合物、其制备方法和用途
CN103435572B (zh) * 2013-07-16 2015-02-04 浙江医药高等专科学校 噻唑并环己烷类化合物、其制备方法和抗肿瘤用途
CN103435573B (zh) * 2013-07-16 2015-04-01 浙江医药高等专科学校 苄基取代的噻唑并环己烷类化合物、其制备方法和用途
CA2940144C (en) 2014-02-20 2023-06-13 Cornell University Substituted indazol-3-yl derivatives and pharmaceutical compositions thereof useful as inhibitor of fascin
DK3169815T3 (da) 2014-07-15 2021-02-15 Ontario Institute For Cancer Res Fremgangsmåder og indretninger til forudsigelse af anthracyclinbehandlingseffektivitet
EP3236966B1 (en) * 2014-12-23 2020-08-12 DOT Therapeutics-1, Inc. Combination of raf inhibitors and taxanes
WO2017066664A1 (en) * 2015-10-16 2017-04-20 Millennium Pharmaceuticals, Inc. Combination therapy including a raf inhibitor for the treatment of colorectal cancer
WO2017165491A1 (en) * 2016-03-24 2017-09-28 Millennium Pharmaceuticals, Inc. Use of a pd-1 antagonist and a raf inhibitor in the treatment of cancer
WO2017165742A1 (en) 2016-03-24 2017-09-28 Millennium Pharmaceuticals, Inc. Methods of treating gastrointestinal immune-related adverse events in anti-ctla4 anti-pd-1 combination treatments
US11760803B2 (en) 2016-03-24 2023-09-19 Takeda Pharmaceutical Company Limited Methods of treating gastrointestinal immune-related adverse events in immune oncology treatments
CN109053630B (zh) * 2018-08-22 2022-04-01 中国人民解放军第二军医大学 一种苯并噻唑类衍生物及其用途
US12415816B2 (en) 2018-11-07 2025-09-16 Dana-Farber Cancer Institute, Inc. Benzothiazole derivatives and 7-aza-benzothiazole derivatives as janus kinase 2 inhibitors and uses thereof
WO2020097400A1 (en) 2018-11-07 2020-05-14 Dana-Farber Cancer Institute, Inc. Imidazopyridine derivatives and aza-imidazopyridine derivatives as janus kinase 2 inhibitors and uses thereof
US12522583B2 (en) 2018-11-07 2026-01-13 Dana-Farber Cancer Institute, Inc. Benzimidazole derivatives and aza-benzimidazole derivatives as Janus kinase 2 inhibitors and uses thereof
WO2020232445A1 (en) * 2019-05-16 2020-11-19 The Regents Of The University Of California Modulators of pyrimidine nucleotide biosynthetic pathways
TW202204350A (zh) 2020-05-06 2022-02-01 美商雅捷可斯治療公司 作為ｊａｋ２抑制劑之６－雜芳基氧基苯并咪唑及氮雜苯并咪唑
CN112094248B (zh) * 2020-09-17 2023-05-12 中国人民解放军海军军医大学 一种取代苯并噻唑类化合物及其用途
US12043632B2 (en) 2020-12-23 2024-07-23 Ajax Therapeutics, Inc. 6-heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors
WO2023086320A1 (en) 2021-11-09 2023-05-19 Ajax Therapeutics, Inc. Forms and compositions of inhibitors of jak2
CA3234638A1 (en) 2021-11-09 2023-05-19 Ajax Therapeutics, Inc. 6-heteroaryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors
CN115724837B (zh) * 2022-10-26 2024-07-23 中国人民解放军海军军医大学 一种抑制程序性细胞坏死的苯并噻唑衍生物及其应用

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2399026A (en) 1941-02-06 1946-04-23 Chem Ind Basel Amides of 2-aminoarylenethiazoles
US4096264A (en) 1975-12-09 1978-06-20 Merck & Co., Inc. Certain substituted imidazo [1,2-a] pyridines
CO4950519A1 (es) 1997-02-13 2000-09-01 Novartis Ag Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
GB9716557D0 (en) 1997-08-06 1997-10-08 Glaxo Group Ltd Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
US6093728A (en) 1997-09-26 2000-07-25 Asta Medica Aktiengesellschaft Methods of modulating serine/threonine protein kinase function with azabenzimidazole-based compounds
ATE538794T1 (de) 1999-01-13 2012-01-15 Bayer Healthcare Llc Gamma carboxyarylsubstituierte diphenylharnstoffverbindungen als p38 kinasehemmer
EP1140840B1 (en) * 1999-01-13 2006-03-22 Bayer Pharmaceuticals Corp. -g(v)-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
US7928239B2 (en) 1999-01-13 2011-04-19 Bayer Healthcare Llc Inhibition of RAF kinase using quinolyl, isoquinolyl or pyridyl ureas
CZ299125B6 (cs) * 1999-01-13 2008-04-30 Bayer Corporation Difenylové mocoviny substituované omega-karboxyarylovou skupinou jako inhibitory rafkinázy, jejich použití a farmaceutické kompozice s jejich obsahem
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
JP3519368B2 (ja) 1999-01-22 2004-04-12 麒麟麦酒株式会社 キノリン誘導体およびキナゾリン誘導体
CA2377771A1 (en) 1999-07-01 2001-01-11 Ajinomoto Co., Inc. Heterocyclic compounds and medical use thereof
PL203782B1 (pl) 1999-11-05 2009-11-30 Astrazeneca Ab Pochodne chinazoliny,sposoby ich wytwarzania,ich kompozycje farmaceutyczne oraz ich zastosowania
JP2003521543A (ja) 2000-02-07 2003-07-15 アボット ゲーエムベーハー ウント カンパニー カーゲー ２−ベンゾチアゾリル尿素誘導体およびそのプロテインキナーゼ阻害剤としての使用
DE122008000002I1 (de) 2000-02-15 2008-04-17 Sugen Inc Pyrrol substituierte indolin-2-on protein kinase inhibitoren
GB0005357D0 (en) 2000-03-06 2000-04-26 Smithkline Beecham Plc Compounds
JP2003525936A (ja) 2000-03-06 2003-09-02 スミスクライン ビーチャム パブリック リミテッド カンパニー Ｒａｆキナーゼ阻害物質としてのイミダゾール誘導体
CZ2003182A3 (cs) 2000-06-21 2003-06-18 F. Hoffmann-La Roche Ag Deriváty benzothiazolu
EP1318992B1 (en) 2000-09-21 2005-07-27 Smithkline Beecham Plc Imidazole derivatives as raf kinase inhibitors
ATE419239T1 (de) 2000-10-20 2009-01-15 Eisai R&D Man Co Ltd Verfahren zur herstellung von 4-phenoxy chinolin derivaten
EP1341771A2 (en) 2000-11-29 2003-09-10 Glaxo Group Limited Benzimidazole derivatives useful as tie-2 and/or vegfr-2 inhibitors
GB0112348D0 (en) 2001-05-19 2001-07-11 Smithkline Beecham Plc Compounds
US7375105B2 (en) 2001-09-05 2008-05-20 Smithkline Beecham P.L.C. Pyridine substituted furan derivatives as Raf kinase inhibitors
GB0121494D0 (en) 2001-09-05 2001-10-24 Smithkline Beecham Plc Compounds
GB0121488D0 (en) 2001-09-05 2001-10-24 Smithkline Beecham Plc Compounds
EP1432703A1 (en) 2001-09-05 2004-06-30 Smithkline Beecham Plc Heterocycle-carboxamide derivatives as raf kinase inhibitors
JP2005524668A (ja) 2002-03-01 2005-08-18 スミスクライン ビーチャム コーポレーション ジアミノピリミジン類及びそれらの血管新生阻害薬としての使用
US7071216B2 (en) 2002-03-29 2006-07-04 Chiron Corporation Substituted benz-azoles and methods of their use as inhibitors of Raf kinase
US8299108B2 (en) 2002-03-29 2012-10-30 Novartis Ag Substituted benzazoles and methods of their use as inhibitors of raf kinase
ES2423800T3 (es) 2003-03-28 2013-09-24 Novartis Vaccines And Diagnostics, Inc. Uso de compuestos orgánicos para la inmunopotenciación
US7378233B2 (en) 2003-04-12 2008-05-27 The Johns Hopkins University BRAF mutation T1796A in thyroid cancers
DE10334663A1 (de) * 2003-07-30 2005-03-10 Merck Patent Gmbh Harnstoffderivate
DE10337942A1 (de) 2003-08-18 2005-03-17 Merck Patent Gmbh Aminobenzimidazolderivate
DE602004021838D1 (de) 2003-10-16 2009-08-13 Novartis Vaccines & Diagnostic Substituierte benzazole und ihre verwendung als raf-kinase-hemmer
AU2005244736B2 (en) 2004-05-07 2012-06-28 Exelixis Patent Company Llc Raf modulators and methods of use
MX2007001155A (es) 2004-07-29 2007-08-14 Creabilis Therapeutics Spa Uso de inhibidores de k-252a y de quinasa para la prevencion o el tratamiento de patologias asociadas con hmgb1.
GB0420719D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
WO2006071035A1 (en) 2004-12-31 2006-07-06 Lg Life Sciences, Ltd. Novel ([1,3]thiazolo[5,4-b]pyridin-2-yl)-2-carboxamide derivatives
WO2006076376A1 (en) 2005-01-11 2006-07-20 Medicinova, Inc. Topical treatment of solid tumors and ocular neovascularization
CN101106990B (zh) * 2005-01-26 2010-12-08 Irm责任有限公司 用作蛋白激酶抑制剂的化合物和组合物
RU2420525C2 (ru) 2005-07-11 2011-06-10 Мицубиси Танабе Фарма Корпорейшн Производные оксимов и их получение
PE20070427A1 (es) 2005-08-30 2007-04-21 Novartis Ag Compuestos derivados de benzimidazoles sustituidos como inhibidores de tirosina quinasas
GT200600429A (es) 2005-09-30 2007-04-30 Compuestos organicos
WO2007058482A1 (en) 2005-11-16 2007-05-24 Lg Life Sciences, Ltd. Novel inhibitors of protein kinase
PL2010528T3 (pl) 2006-04-19 2018-03-30 Novartis Ag 6-0-podstawione związki benzoksazolowe i benzotiazolowe i sposoby hamowania sygnalizacji csf-1r
JP5238697B2 (ja) 2006-08-04 2013-07-17 武田薬品工業株式会社 縮合複素環誘導体およびその用途
EP2058309A4 (en) 2006-08-04 2010-12-22 Takeda Pharmaceutical CONDENSED HETEROCYCLIC COMPOUND
JP4328820B2 (ja) 2007-01-10 2009-09-09 田辺三菱製薬株式会社 医薬組成物
WO2008084873A1 (ja) 2007-01-10 2008-07-17 Mitsubishi Tanabe Pharma Corporation オキシム誘導体
CN101260106A (zh) * 2007-03-06 2008-09-10 中国药科大学 Raf激酶抑制剂及其制备方法和用途
WO2008125633A2 (en) 2007-04-13 2008-10-23 Rikshospitalet - Radiumhospitalet Hf Egfr inhibitors for treatment and diagnosis of metastatic prostate cancer
WO2008141275A1 (en) 2007-05-11 2008-11-20 The Johns Hopkins University Biomarkers for melanoma
JP2010528032A (ja) 2007-05-23 2010-08-19 ノバルティス アーゲー 甲状腺癌の処置のためのｒａｆ阻害剤
CA2689514C (en) 2007-06-05 2015-09-29 Takeda Pharmaceutical Company Limited Heterobicyclic compounds as kinase inhibitors
JP2008307581A (ja) 2007-06-15 2008-12-25 Sanyo Special Steel Co Ltd 管材の洗浄装置
JP5270553B2 (ja) 2007-08-23 2013-08-21 武田薬品工業株式会社 複素環化合物およびその用途
JP5350247B2 (ja) 2007-08-29 2013-11-27 武田薬品工業株式会社 複素環化合物およびその用途
WO2009028655A1 (ja) 2007-08-30 2009-03-05 Takeda Pharmaceutical Company Limited 複素環化合物およびその用途
JP2009125256A (ja) 2007-11-22 2009-06-11 Kandado:Kk 安眠枕
CN101220024A (zh) * 2007-12-11 2008-07-16 杜晓敏 一组抑制激酶的抗癌化合物
US20110081362A1 (en) 2008-01-31 2011-04-07 The Brigham And Women's Hospital, Inc. Treatment of cancer
US20090275546A1 (en) 2008-04-10 2009-11-05 Istituto Superiore Di Sanita Diagnostic tests and personalized treatment regimes for cancer stem cells
US8445509B2 (en) 2008-05-08 2013-05-21 Takeda Pharmaceutical Company Limited Fused heterocyclic derivatives and use thereof

Also Published As

Publication number Publication date
HUE026491T2 (en) 2016-06-28
AR074435A1 (es) 2011-01-19
HRP20151370T1 (hr) 2016-01-15
EA019447B1 (ru) 2014-03-31
JP5640014B2 (ja) 2014-12-10
CN102300854A (zh) 2011-12-28
DK2358689T5 (en) 2016-10-10
NZ593759A (en) 2012-07-27
CY1117178T1 (el) 2017-04-05
MX2011005836A (es) 2011-06-17
SMT201500316B (it) 2016-01-08
CL2011001299A1 (es) 2012-01-13
CN102300854B (zh) 2015-01-07
KR101639092B1 (ko) 2016-07-12
DK2358689T3 (en) 2015-12-14
RS54370B9 (sr) 2020-01-31
SG171426A1 (en) 2011-07-28
DOP2011000165A (es) 2011-06-30
TWI436987B (zh) 2014-05-11
CA2745144A1 (en) 2010-06-10
EP2358689B1 (en) 2015-09-30
GEP20146003B (en) 2014-01-10
PE20110588A1 (es) 2011-09-08
PT2358689E (pt) 2015-12-30
AU2009323274B2 (en) 2015-09-17
IL213184A0 (en) 2011-07-31
MY150989A (en) 2014-03-31
HUE026491T4 (en) 2017-07-28
UY32281A (es) 2010-06-30
KR20110091039A (ko) 2011-08-10
US8143258B2 (en) 2012-03-27
ECSP11011165A (es) 2011-07-29
EP2358689A1 (en) 2011-08-24
CA2745144C (en) 2017-10-03
PL2358689T3 (pl) 2016-03-31
WO2010064722A1 (en) 2010-06-10
JO3101B1 (ar) 2017-09-20
US20120214855A1 (en) 2012-08-23
BRPI0922109A2 (pt) 2020-09-01
EA201170735A1 (ru) 2011-12-30
US8497274B2 (en) 2013-07-30
CO6400140A2 (es) 2012-03-15
ME02331B (me) 2016-04-28
TW201024272A (en) 2010-07-01
JP2012510467A (ja) 2012-05-10
EP2358689B9 (en) 2016-08-03
AU2009323274A1 (en) 2011-07-07
HK1161236A1 (zh) 2012-08-24
SI2358689T1 (sl) 2016-01-29
MA32911B1 (fr) 2011-12-01
US20100216810A1 (en) 2010-08-26
RS54370B1 (sr) 2016-04-28
ZA201104659B (en) 2012-08-29
TN2011000280A1 (en) 2012-12-17
ES2557304T3 (es) 2016-01-25

Similar Documents

Publication Publication Date Title
CR20110366A (es) Compuesto heterociclico y uso del mismo
ECSP10010355A (es) Arilpirrolinas insecticidas
CR20140180A (es) Inhibidores macrocíclicos de serina proteasas de hepatitis c
BRPI0816769A2 (pt) combinações de compostos inibidores de fosfoinositida 3-cinase e agentes quimioterapêuticos, e métodos de uso
CO7160059A2 (es) Formulación líquida
CR10847A (es) Compuesto heteromonociclico y uso del mismo
CL2008001038A1 (es) Uso de una composicion que comprende un antagonosta h1, y un compuesto anti-tnf alfa para tratar conjuntivitis alegica o rinitis alergiva en un sujeto humano
BRPI0907435A8 (pt) derivados de 5-flúor pirimidina
ECSP11011411A (es) Derivados de prolina como inhibidores de catepsina
BRPI0915134A2 (pt) composto, e, uso de um composto
EA201270254A1 (ru) Производные 5-фторпиримидинона
UY29826A1 (es) Derivados de pirimidina, sales farmaceuticamente aceptables, esteres de los mismos hidrolisables in vivo, procesos de preparacion y aplicaciones
SV2011003853A (es) Compuestos organicos
ES2570569T3 (es) Compuestos de benzoxazepina como inhibidores de la PI3K y métodos de uso
EP1984239A4 (en) DIVING SUIT WITH DOUBLE LAYER
CL2011002370A1 (es) Procedimiento de preparacion de un inhibidor de citrocromo p450 monoxigenasa y los compuestos intermediarios considerados.
BR112012015366A2 (pt) compostos de fórmula (i), uso cosmético e uso de um composto
BRPI0808172A2 (pt) Compostos heterocíclicos, composições compreendendo-os e métodos de seu uso.
CL2010001361A1 (es) Compuestos derivados de piperidin-carboxamida, inhibidores de renina; composicion farmaceutica que los comprende; y uso en el tratamiento o prevencion de una enfermedad circulatoria, hipertension y/o diversos daños organicos atribuibles a la hipertension.
CL2011000846A1 (es) Compuestos heterociclicos sustituidos; composicion farmaceutica; y su uso para el tratamiento de la hepatitis c.
CL2008002049A1 (es) Compuestos derivados de aminoindol macrociclicos; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la hepatitis c.
CR11765A (es) Derivados de iminopiridina y su uso
DE602008005141D1 (de) 1,3-dihydroimidazol-2-thionderivate als inhibitoren von dopamin-beta-hydroxylase
ECSP088925A (es) Nitrilos espirocíclicos como inhibidores de proteasa
BRPI0921044A2 (pt) composto heterocíclico de acenafto, composto de inclusão de ciclodextrina do composto heterocíclico de acenafto, complexo de ciclodextrina do composto heterocíclico de acenafto, uso do composto heterocíclico de acenafto, uso do composto de inclusão de ciclodextrina do composto heterocíclico de acenafto e uso do complexo de ciclodextrina